Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies

Published:2021-02 Issue: Volume:148 Page:134-140
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Hollenbeck Brent K.,Oerline Mary,Kaufman Samuel R.,Caram Megan E.V.,Dusetzina Stacie B.,Ryan Andy M.,Shahinian Vahakn B.

Funder

Agency for Healthcare Research and Quality

Publisher

Elsevier BV

Subject

Urology

Reference33 articles.

1. Prostate Cancer Costs of Care Projections,2016

2. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy;Harland;Eur J Cancer,2013

5. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial;Basch;Lancet Oncol,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic “Advances”;Journal of Urology;2024-02

2. Impact of the Inflation Reduction Act for Patients With Advanced Prostate Cancer;Urology Practice;2023-11

3. Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Medicare Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity;Urology Practice;2023-09

4. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide;Urology;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3